These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30972782)

  • 1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
    Lozano E; Macias RIR; Monte MJ; Asensio M; Del Carmen S; Sanchez-Vicente L; Alonso-Peña M; Al-Abdulla R; Munoz-Garrido P; Satriano L; O'Rourke CJ; Banales JM; Avila MA; Martinez-Chantar ML; Andersen JB; Briz O; Marin JJG
    Hepatology; 2019 Oct; 70(4):1246-1261. PubMed ID: 30972782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
    Al-Abdulla R; Lozano E; Macias RIR; Monte MJ; Briz O; O'Rourke CJ; Serrano MA; Banales JM; Avila MA; Martinez-Chantar ML; Geier A; Andersen JB; Marin JJG
    Br J Pharmacol; 2019 Mar; 176(6):787-800. PubMed ID: 30592786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.
    Lozano E; Asensio M; Perez-Silva L; Banales JM; Briz O; Marin JJG
    Hepatology; 2020 Sep; 72(3):949-964. PubMed ID: 31863486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
    Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line.
    Iwaki J; Kikuchi K; Mizuguchi Y; Kawahigashi Y; Yoshida H; Uchida E; Takizawa T
    PLoS One; 2013; 8(7):e69496. PubMed ID: 23922722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting
    Changphasuk P; Inpad C; Horpaopan S; Khunchai S; Phimsen S; Surangkul D; Janvilisri T; Silsirivanit A; Kaewkong W
    Front Biosci (Schol Ed); 2024 Sep; 16(3):17. PubMed ID: 39344395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
    Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
    Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
    Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
    Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide.
    Ortiz-Rivero S; Peleteiro-Vigil A; Abete L; Lozano E; Hammer HS; Giacomo SD; Abad M; Boix L; Forner A; Reig M; Macias RIR; Pötz O; Marin JJG; Briz O
    Biomed Pharmacother; 2024 Jan; 170():116038. PubMed ID: 38141281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
    Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
    Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT).
    Lozano E; Monte MJ; Briz O; Hernández-Hernández A; Banales JM; Marin JJ; Macias RI
    J Control Release; 2015 Oct; 216():93-102. PubMed ID: 26278512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte nuclear factor 6 inhibits the growth and metastasis of cholangiocarcinoma cells by regulating miR-122.
    Zhu H; Mi Y; Jiang X; Zhou X; Li R; Wei Z; Jiang H; Lu J; Sun X
    J Cancer Res Clin Oncol; 2016 May; 142(5):969-80. PubMed ID: 26825606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.
    Li L; Piontek K; Ishida M; Fausther M; Dranoff JA; Fu R; Mezey E; Gould SJ; Fordjour FK; Meltzer SJ; Sirica AE; Selaru FM
    Hepatology; 2017 Feb; 65(2):501-514. PubMed ID: 27474881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells.
    Li W; Sun Z; Chen C; Wang L; Geng Z; Tao J
    Biomed Pharmacother; 2018 Apr; 100():257-266. PubMed ID: 29438839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.